Tolerance, adherence, and acceptability of a ketogenic 2.5:1 ratio, nutritionally complete, medium chain triglyceride-containing liquid feed in children and adults with drug-resistant epilepsy following a ketogenic diet.
enteral feed
gastrointestinal tolerance
ketogenic diet
medium chain triglycerides
seizures
Journal
Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
revised:
22
01
2024
received:
17
11
2023
accepted:
23
01
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
27
2
2024
Statut:
aheadofprint
Résumé
To investigate incorporating a ready-to-use 2.5:1 ratio liquid feed into a ketogenic diet (KD) in children and adults with drug-resistant epilepsy. Following a three-day baseline, patients (n = 19; age: 19 years [SD 13], range: 8-46 years) followed a KD for 28 days (control period), then incorporated ≥200 mL/day of a ready-to-use liquid feed, made with a ratio of 2.5 g of fat to 1 g of protein plus carbohydrate and including medium chain triglycerides ([MCTs]; 25.6% of total fat/100 mL) for 28 days as part of their KD (intervention period). Outcome measures (control vs intervention period) included gastrointestinal (GI) tolerance, adherence to KD and intervention feed, dietary intake, blood ß-hydroxybutyrate (BHB) concentration, seizure outcomes, health-related quality of life (HRQoL), acceptability and safety. Compared to the control period, during the intervention period, the percentage of patients reporting no GI symptoms increased (+5% [SD 5], p = 0.02); adherence to the KD prescription was similar (p = 0.92) but higher in patients (n = 5) with poor adherence (<50%) to KD during the control period (+33% [SD 26], p = 0.049); total MCT intake increased (+12.1 g/day [SD 14.0], p = 0.002), driven by increases in octanoic (C8; +8.3 g/day [SD 6.4], p < 0.001) and decanoic acid (C10; +5.4 g/day [SD 5.4], p < 0.001); KD ratio decreased (p = 0.047), driven by a nonsignificant increase in protein intake (+11 g/day [SD 44], p = 0.29); seizure outcomes were similar (p ≥ 0.63) but improved in patients (n = 6) with the worst seizure outcomes during the control period (p = 0.04); and HRQoL outcomes were similar. The intervention feed was well adhered to (96% [SD 8]) and accepted (≥88% of patients confirmed). These findings provide an evidence-base to support the effective management of children and adults with drug-resistant epilepsy following a KD with the use of a ready-to-use, nutritionally complete, 2.5:1 ratio feed including MCTs. This study examined the use of a ready-to-use, nutritionally complete, 2.5:1 ratio (2.5 g of fat to 1 g of protein plus carbohydrate) liquid feed, including medium chain triglycerides (MCTs), into a ketogenic diet (KD) in children and adults with drug-resistant epilepsy. The results show that the 2.5:1 ratio feed was well tolerated, adhered to, and accepted in these patients. Increases in MCT intake (particularly C8 and C10) and improvements in seizure outcomes (reduced seizure burden and intensity) and KD adherence also occurred with the 2.5:1 ratio feed in patients with the worst seizures and adherence, respectively.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Nutricia Ltd.
Informations de copyright
© 2024 Nutricia Ltd. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Barzegar M, Afghan M, Tarmahi V, Behtari M, Rahimi Khamaneh S, Raeisi SJN. Ketogenic diet: overview, types, and possible anti-seizure mechanisms. Nutr Neurosci. 2021;24:307-316.
National Institue for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. https://www.nice.org.uk/guidance/ng217. Accessed 23 Feb 2023
Kossoff EH, McGrogan JR. Worldwide use of the ketogenic diet. Epilepsia. 2005;46:280-289.
Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology. 1971;21:1097-1103.
Liu Y-M, Wang H-S. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biom J. 2013;36:9-15.
Martin-McGill KJ, Lambert BA, Whiteley VJ, Wood S, Neal EG, Simpson ZR, et al. Understanding the core principles of a modified ketogenic diet: a UK and Ireland perspective. J Hum Nutr Diet. 2019;32:385-390.
Raju KV, Gulati S, Kabra M, Agarwala A, Sharma S, Pandey RM, et al. Efficacy of 4:1 (classic) versus 2.5:1 ketogenic ratio diets in refractory epilepsy in young children: a randomized open labeled study. Epilepsy Res. 2011;96:96-100.
Sondhi V, Agarwala A, Pandey RM, Chakrabarty B, Jauhari P, Lodha R, et al. Efficacy of ketogenic diet, modified atkins diet, and low glycemic index therapy diet among children with drug-resistant epilepsy: a randomized clinical trial. JAMA Pediatr. 2020;174:944-951.
Ye F, Li XJ, Jiang WL, Sun HB, Liu J. Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: a meta-analysis. Neurology. 2015;11:26-31.
Payne NE, Cross JH, Sander JW, Sisodiya SMJE. The ketogenic and related diets in adolescents and adults-a review. Epilepsia. 2011;52:1941-1948.
Nei M, Ngo L, Sirven JI, Sperling MR. Ketogenic diet in adolescents and adults with epilepsy. Seizure. 2014;23:439-442.
Cai QY, Zhou ZJ, Luo R, Gan J, Li SP, Mu DZ, et al. Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies. World J Pediatr. 2017;13:528-536.
Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020;6:CD001903.
Zarnowska IM. Therapeutic use of the ketogenic diet in refractory epilepsy: what we know and what still needs to be learned. Nutrients. 2020;12:2616.
Operto FF, Labate A, Aiello S, Perillo C, de Simone V, Rinaldi R, et al. The ketogenic diet in children with epilepsy: a focus on parental stress and family compliance. Nutrients. 2023;15:1058.
Augustin K, Khabbush A, Williams S, Eaton S, Orford M, Cross JH, et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol. 2018;17:84-93.
Seo JH, Lee YM, Lee JS, Kang HC, Kim HD. Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios - comparison of 3:1 with 4:1 diet. Epilepsia. 2007;48:801-805.
El-Rashidy OF, Nassar MF, Hamid IA, Shatla RH, Hamid MH, Gabr SS. Modified Atkins diet vs classic ketogenic formula in intractable epilepsy. Acta Neurol Scand. 2013;128:402-408.
Lambrechts DA, Wielders LH, Aldenkamp AP, Kessels FG, de Kinderen RJ, Majoie MJ. The ketogenic diet as a treatment option in adults with chronic refractory epilepsy: efficacy and tolerability in clinical practice. Epilepsy Behav. 2012;23:310-314.
Griffen C, Delsoglio M, Syed R, Cookson T, Saliba H, Vowles A, et al. A ready to drink, plant-based oral nutritional supplement is highly complied with, palatable and tolerated in community-based patients at risk of disease-related malnutrition. Clinical Nutrition ESPEN. 2023;54:706.
Green BP, Wong E, Andrews S, Hampshire-Jones K, McKinnon S, Brooks C, et al. Increased protein intake is associated with improved hand grip strength and quality of life in home enterally tube fed adults using a high-energy, high-protein feed. Clinical Nutrition ESPEN. 2020;35:208.
Hubbard GP, Fry C, Sorensen K, Casewell C, Collins L, Cunjamalay A, et al. Energy-dense, low-volume paediatric oral nutritional supplements improve total nutrient intake and increase growth in paediatric patients requiring nutritional support: results of a randomised controlled pilot trial. Eur J Pediatr. 2020;179:1-10.
Delsoglio M, Griffen C, Syed R, Cookson T, Saliba H, Vowles A, et al. A multi-centre prospective study of plant-based nutritional support in adult community-based patients at risk of disease-related malnutrition. Front Nutr. 2023;10:1297624.
Liu YM, Wang HS. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biom J. 2013;36:9-15.
Muscaritoli M, Pradelli LJ. Medium-chain triglyceride (MCT) content of adult enteral tube feeding formulas and clinical outcomes. A systematic review. Front Nutr. 2021;8:697529.
Switkowski KM, Jacques PF, Must A, Fleisch A, Oken EJ. Associations of protein intake in early childhood with body composition, height, and insulin-like growth factor I in mid-childhood and early adolescence. Am J Clin Nutr. 2019;109:1154-1163.
Deutz NE, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN expert group. Clin Nutr. 2014;33:929-936.
Griffen C, Duncan M, Hattersley J, Weickert MO, Dallaway A, Renshaw D. Effects of resistance exercise and whey protein supplementation on skeletal muscle strength, mass, physical function, and hormonal and inflammatory biomarkers in healthy active older men: a randomised, double-blind, placebo-controlled trial. Exp Gerontol. 2022;158:111651.
Griffen C, Renshaw D, Duncan M, Weickert MO, Hattersley J. Changes in 24-h energy expenditure, substrate oxidation, and body composition following resistance exercise and a high protein diet via whey protein supplementation in healthy older men. Physiol Rep. 2022;10:e15268.
Schoeler NE, Cross JH. Ketogenic dietary therapies in adults with epilepsy: a practical guide. Pract Neurol. 2016;16:208-214.
van der Louw E, van den Hurk D, Neal E, Leiendecker B, Fitzsimmon G, Dority L, et al. Ketogenic diet guidelines for infants with refractory epilepsy. Eur J Paediatr Neurol. 2016;20:798-809.
van Delft R, Lambrechts D, Verschuure P, Hulsman J, Majoie M. Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine. Seizure. 2010;19:36-39.
Schoeler NE, Cross JH, Sander JW, Sisodiya SM. Can we predict a favourable response to ketogenic diet therapies for drug-resistant epilepsy? Epilepsy Res. 2013;106:1-16.
Akdemir V, Sut N, Godlike B. Factors affecting the quality of life in drug-resistant epilepsy patients. Acta Neurol Belg. 2016;116:513-518.
Lu H-H, Tsai C-Y, Chou I, Tsai J. The impact of parenting stress on parents of school-age children with drug-resistant epilepsy. Front Pediatr. 2022;10:948286.
Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia. 1997;38:353-362.
Kverneland M, Nakken KO, Hofoss D, Skogan AH, Iversen PO, Selmer KK, et al. Health-related quality of life in adults with drug-resistant focal epilepsy treated with modified Atkins diet in a randomized clinical trial. Epilepsia. 2023;64:e69-e74.
Sourbron J, Klinkenberg S, van Kuijk SM, Lagae L, Lambrechts D, Braakman HM, et al. Ketogenic diet for the treatment of pediatric epilepsy: review and meta-analysis. Childs Nerv Syst. 2020;36:1099-1109.
Beaton GH, Milner J, McGuire V, Feather TE, Little JA. Source of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation. Carbohydrate sources, vitamins, and minerals. Am J Clin Nutr. 1983;37:986-995.